{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:51:07Z","timestamp":1790351467093,"version":"4.1.0"},"reference-count":136,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The publication focuses on the innovative applications of PROTAC (proteolysis-targeting chimera) technology in modern pharmacotherapy, with particular emphasis on cancer treatment. PROTACs represent an advanced therapeutic strategy that enables selective protein degradation, opening new possibilities in drug design. This technology shows potential in the treatment of cancers, viral infections (such as HIV and COVID-19), and chronic diseases including atherosclerosis, Alzheimer\u2019s disease, atopic dermatitis, and Huntington\u2019s disease. Promising results from clinical studies on the compound ARV-471 confirm the effectiveness of this approach. New types of PROTACs, like TF-PROTAC and PhosphoTAC, are designed to enhance the effectiveness, stability, and absorption of treatment drugs. The conclusions of the review highlight the broad therapeutic potential of PROTACs in various diseases and their relevance for the future of therapies, particularly in oncology.<\/jats:p>","DOI":"10.3390\/molecules30102123","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T06:17:08Z","timestamp":1747030628000},"page":"2123","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["PROTAC Technology as a New Tool for Modern Pharmacotherapy"],"prefix":"10.3390","volume":"30","author":[{"given":"Natalia","family":"Kubry\u0144","sequence":"first","affiliation":[{"name":"Department of Organic Chemistry, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru\u0144, 2 dr. A. Jurasza St., 85-094 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6778-8259","authenticated-orcid":false,"given":"\u0141ukasz","family":"Fija\u0142kowski","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru\u0144, 2 dr. A. Jurasza St., 85-094 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4521-8065","authenticated-orcid":false,"given":"Jacek","family":"Nowaczyk","sequence":"additional","affiliation":[{"name":"Department of Physical Chemistry and Physicochemistry of Polymers, Faculty of Chemistry, Nicolaus Copernicus University, 7 Gagarina St., 87-100 Toru\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4039-4166","authenticated-orcid":false,"given":"Amer","family":"Jamil","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Agriculture, Faisalabad 38040, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4945-2369","authenticated-orcid":false,"given":"Alicja","family":"Nowaczyk","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru\u0144, 2 dr. A. Jurasza St., 85-094 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics","volume":"69","author":"Siegel","year":"2019","journal-title":"CA A Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: An evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs)\u2014Past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"116096","DOI":"10.1016\/j.ejmech.2023.116096","article-title":"Progress in the controllability technology of PROTAC","volume":"265","author":"He","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cbf.3369","article-title":"The PROTAC technology in drug development","volume":"37","author":"Zou","year":"2019","journal-title":"Cell Biochem. Funct."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev-pharmtox-010715-103507","article-title":"Targeted Protein Degradation by Small Molecules","volume":"57","author":"Bondeson","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"114838","DOI":"10.1016\/j.ejmech.2022.114838","article-title":"A bibliometric analysis of PROTAC from 2001 to 2021","volume":"244","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"116725","DOI":"10.1016\/j.ejmech.2024.116725","article-title":"PROTAC technology: From drug development to probe technology for target deconvolution","volume":"276","author":"Yan","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2314132","DOI":"10.1002\/adma.202314132","article-title":"PROTAC Prodrug-Integrated Nanosensitizer for Potentiating Radiation Therapy of Cancer","volume":"36","author":"Zhang","year":"2024","journal-title":"Adv. Mater."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e00548","DOI":"10.1016\/j.neurot.2025.e00548","article-title":"Proteolytic therapeutic modalities for amyloidoses: Insights into immunotherapy, PROTAC, and photo-oxygenation","volume":"22","author":"Kuriyama","year":"2025","journal-title":"Neurotherapeutics"},{"key":"ref_16","first-page":"99","article-title":"PROTAC technology for prostate cancer treatment","volume":"4","author":"Wang","year":"2025","journal-title":"Acta Mater. Medica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1021\/acs.jmedchem.5c00026","article-title":"Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC)","volume":"68","author":"Monsen","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.chembiol.2022.08.004","article-title":"Target protein localization and its impact on PROTAC-mediated degradation","volume":"29","author":"Simpson","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1021\/acsmedchemlett.4c00500","article-title":"Clozapine as an E3 Ligand for PROTAC Technology","volume":"16","author":"Takano","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_20","first-page":"445","article-title":"Advances in the optimization of the linker in proteolysis-targeting chimeras (PROTAC)","volume":"12","author":"Sheng","year":"2021","journal-title":"Acta Pharm. Sinica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"390a","DOI":"10.1016\/j.bpj.2024.11.2107","article-title":"BPS2025-Innovative strategies in PROTAC design: Evaluating linker efficiency through protein frustration analysis","volume":"124","author":"Ma","year":"2025","journal-title":"Biophys. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.37349\/etat.2020.00018","article-title":"Current strategies for the design of PROTAC linkers: A critical review","volume":"1","author":"Troup","year":"2020","journal-title":"Explor. Target. Anti-tumor Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/acsmedchemlett.5c00068","article-title":"Linker-Determined Folding and Hydrophobic Interactions Explain a Major Difference in PROTAC Cell Permeability","volume":"16","author":"Poongavanam","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1021\/acs.jmedchem.4c02492","article-title":"Impact of Linker Composition on VHL PROTAC Cell Permeability","volume":"68","author":"Abeje","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acsmedchemlett.4c00189","article-title":"Interplay of PROTAC Complex Dynamics for Undruggable Targets: Insights into Ternary Complex Behavior and Linker Design","volume":"15","author":"Kumar","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41392-020-00245-0","article-title":"In vivo target protein degradation induced by PROTACs based on E3 ligase DCAF15","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1021\/acschembio.8b01083","article-title":"Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications","volume":"14","author":"Ward","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1021\/acs.biochem.1c00464","article-title":"Ligandability of E3 Ligases for Targeted Protein Degradation Applications","volume":"62","author":"Belcher","year":"2021","journal-title":"Biochemistry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1152\/physiolgenomics.00031.2016","article-title":"Comprehensive database of human E3 ubiquitin ligases: Application to aquaporin-2 regulation","volume":"48","author":"Medvar","year":"2016","journal-title":"Physiol. Genom."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Jamal, M.S., Song, K.-S., Lee, K.-W., Kim, J.-J., and Park, Y.-M. (2023). Revolutionizing drug targeting strategies: Integrating artificial intelligence and structure-based methods in PROTAC development. Pharmaceuticals, 16.","DOI":"10.3390\/ph16121649"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/cbdd.14123","article-title":"ELIOT: A platform to navigate the E3 pocketome and aid the design of new PROTACs","volume":"101","author":"Palomba","year":"2023","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.37349\/etat.2020.00023","article-title":"Novel approaches for the rational design of PROTAC linkers","volume":"1","author":"Zagidullin","year":"2020","journal-title":"Explor. Target. Anti-Tumor Ther."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Wang, S., He, F., Tian, C., and Sun, A. (2024). From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation. Pharmaceuticals, 17.","DOI":"10.3390\/ph17010100"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1021\/acs.jcim.1c01036","article-title":"Impact of PROTAC Linker Plasticity on the Solution Conformations and Dissociation of the Ternary Complex","volume":"62","author":"Weerakoon","year":"2022","journal-title":"J. Chem. Inf. Model."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1517\/17460440802579975","article-title":"Small-molecule inhibitors binding to protein kinases. Part I: Exceptions from the traditional pharmacophore approach of type I inhibition","volume":"3","author":"Backes","year":"2008","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Xiao, M., Zhao, J., Wang, Q., Liu, J., and Ma, L. (2022). Recent Advances of Degradation Technologies Based on PROTAC Mechanism. Biomolecules, 12.","DOI":"10.3390\/biom12091257"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"110446","DOI":"10.1016\/j.cellsig.2022.110446","article-title":"The mechanism of action and clinical value of PROTACs: A graphical review","volume":"99","author":"Graham","year":"2022","journal-title":"Cell. Signal."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"GS3-03","DOI":"10.1158\/1538-7445.SABCS22-GS3-03","article-title":"Abstract GS3-03: GS3-03 ARV-471, a PROTAC\u00ae estrogen receptor (ER) degrader in advanced ER-positive\/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: Phase 2 expansion (VERITAC) of a phase 1\/2 study","volume":"83","author":"Schott","year":"2023","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1538-7445.AM2021-44","article-title":"Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer","volume":"81","author":"Snyder","year":"2021","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1021\/acs.jmedchem.8b00909","article-title":"Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression","volume":"62","author":"Li","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101062","DOI":"10.1016\/j.xcrp.2022.101062","article-title":"Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy","volume":"3","author":"Han","year":"2022","journal-title":"Cell Rep. Phys. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","article-title":"Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4\/6 or PI3K\/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models","volume":"30","author":"Gough","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Nguyen, T.-T., Kim, J.W., Choi, H.-I., Maeng, H.-J., and Koo, T.-S. (2022). Development of an LC-MS\/MS Method for ARV-110, a PROTAC Molecule, and Applications to Pharmacokinetic Studies. Molecules, 27.","DOI":"10.3390\/molecules27061977"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4155\/fmc-2021-0223","article-title":"Challenges and Opportunities for In Vivo PROTAC Delivery","volume":"14","author":"Benowitz","year":"2022","journal-title":"Futur. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Ma, L., and Han, X. (2025). Bavdegalutamide (ARV-110): A potent PROTAC androgen receptor degrader for the treatment of metastatic-castration resistant prostate cancer. Drug Discovery Stories, Elsevier.","DOI":"10.1016\/B978-0-443-23932-8.00020-0"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-cancerbio-061824-105806","article-title":"Development of PROTAC Degrader Drugs for Cancer","volume":"9","author":"Vetma","year":"2024","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1200\/JCO.2019.37.7_suppl.259","article-title":"ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer","volume":"37","author":"Neklesa","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Grigoreva, T.A., Novikova, D.S., Melino, G., Barlev, N.A., and Tribulovich, V.G. (2024). Ubiquitin recruiting chimera: More than just a PROTAC. Biol. Direct, 19.","DOI":"10.1186\/s13062-024-00497-8"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"P5-04-18","DOI":"10.1158\/1538-7445.SABCS18-P5-04-18","article-title":"Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer","volume":"79","author":"Flanagan","year":"2019","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"17588359221113694","DOI":"10.1177\/17588359221113694","article-title":"Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: Current and emerging role","volume":"14","author":"Lloyd","year":"2022","journal-title":"Ther. Adv. Med Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.annonc.2024.09.005","article-title":"Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Rathkopf","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JCO.2024.42.4_suppl.124","article-title":"Preliminary data from a dose-escalation phase 1 study with HP518, an AR PROTAC degrader: Safety, tolerability, pharmacokinetics (PK), and first assessment of anti-tumor activity in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Azad","year":"2024","journal-title":"Am. Soc. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.18632\/oncoscience.600","article-title":"Restoring our ubiquitination machinery to overcome resistance in cancer therapy","volume":"11","author":"Li","year":"2024","journal-title":"Oncoscience"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1039\/D4MD00769G","article-title":"Property-based optimisation of PROTACs","volume":"16","author":"Scott","year":"2024","journal-title":"RSC Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.apsb.2023.09.003","article-title":"Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies","volume":"14","author":"Peng","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cpt.2985","article-title":"Clinical Translation of Targeted Protein Degraders","volume":"114","author":"Kong","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_58","unstructured":"Park, E.S., Ahn, J.Y., Baddour, J., Chaturvedi, P., Chiu, M.I., Cole, K.S., Crystal, A.S., Duplessis, M., Fisher, S.L., and Good, A.C. (2021). Preclinical Evaluation of CFT8919 as a Mutant Selective Degrader of EGFR with L858R Activating Mutations for the Treatment of Non-Small Cell Lung Cancer; Keystone Esymposium Targeting Protein Degradation: From Small Molecules to Complex Organelles, C4 Therapeutics Inc."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"CT128","DOI":"10.1158\/1538-7445.AM2023-CT128","article-title":"Abstract CT128: Phase 1 study of HSK29116, a Bruton tyrosine kinase (BTK) proteolysis-targeting chimera (PROTAC) agent, in patients with relapsed or refractory B-cell malignancies","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2021-147473","article-title":"Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies","volume":"138","author":"Robbins","year":"2021","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2022-164772","article-title":"NX-2127-001, a first-in-human trial of NX-2127, a Bruton\u2019s tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies","volume":"140","author":"Mato","year":"2022","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/1078-0432.CCR-24-2583","article-title":"A Phase I Study of FHD-609, a Heterobifunctional degrader of Bromodomain-containing Protein 9, in patients with advanced synovial sarcoma or SMARCB1-deficient tumors","volume":"4","author":"Livingston","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"ND09","DOI":"10.1158\/1538-7445.AM2022-ND09","article-title":"Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers","volume":"82","author":"Jackson","year":"2022","journal-title":"Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"TPS764","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS764","article-title":"Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations","volume":"41","author":"Tolcher","year":"2023","journal-title":"Am. Soc. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1111\/bph.17332","article-title":"Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton\u2019s tyrosine kinase-targeted protein degrader BGB-16673","volume":"181","author":"Wu","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"S494","DOI":"10.1016\/S2152-2650(24)01558-1","article-title":"AC676, an Orally Bioavailable BTK Chimeric Degrader in Patients With B-cell Malignancies","volume":"24","author":"Patel","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00928-9","article-title":"DT2216\u2014A Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41587-022-01381-4","article-title":"Generation of a live attenuated influenza A vaccine by proteolysis targeting","volume":"40","author":"Si","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Zhang, C., Hou, J., Li, Z., Shen, Q., Bai, H., Chen, L., Shen, J., Wang, P., Su, Y., and Li, J. (2025). PROTAR Vaccine 2.0 generates influenza vaccines by degrading multiple viral proteins. Nat. Chem. Biol., 1\u201311.","DOI":"10.1038\/s41589-024-01813-z"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e1081","DOI":"10.1002\/ctm2.1081","article-title":"PROTAC vaccine: A new way to live attenuated vaccines","volume":"12","author":"Li","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Ahmad, H., Zia, B., Husain, H., and Husain, A. (2023). Recent advances in PROTAC-based antiviral strategies. Vaccines, 11.","DOI":"10.3390\/vaccines11020270"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Luo, D., Luo, R., Wang, W., Deng, R., Wang, S., Ma, X., Pu, C., Liu, Y., Zhang, H., and Yu, S. (2024). Discovery of L15 as a novel Vif PROTAC degrader with antiviral activity against HIV-1. Bioorganic Med. Chem. Lett., 111.","DOI":"10.1016\/j.bmcl.2024.129880"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.chembiol.2024.02.004","article-title":"PROTAC-mediated degradation of HIV-1 Nef efficiently restores cell-surface CD4 and MHC-I expression and blocks HIV-1 replication","volume":"31","author":"Tice","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1021\/acs.jmedchem.3c02416","article-title":"Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease","volume":"67","author":"Alugubelli","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.cell.2022.04.004","article-title":"Atherosclerosis: Recent developments","volume":"185","author":"Lusis","year":"2022","journal-title":"Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jcmg.2018.04.015","article-title":"Effects of statins on coronary atherosclerotic plaques: The PARADIGM study","volume":"11","author":"Lee","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1038\/s41401-023-01088-5","article-title":"Bioinspired PROTAC-induced macrophage fate determination alleviates atherosclerosis","volume":"44","author":"Huang","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Ma, Y., Yang, X., Ning, K., and Guo, H. (2024). M1\/M2 macrophage-targeted nanotechnology and PROTAC for the treatment of atherosclerosis. Life Sci., 122811.","DOI":"10.1016\/j.lfs.2024.122811"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"104044","DOI":"10.1016\/j.drudis.2024.104044","article-title":"Exosome-mediated PROTAC delivery for treatment of RNA viral infections and zoonosis","volume":"29","author":"Mukerjee","year":"2024","journal-title":"Drug Discov. Today"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"100071","DOI":"10.1016\/j.ntm.2025.100071","article-title":"PROTAC-based therapeutics for targeting HPV oncoproteins in head and neck cancers","volume":"4","author":"Mukerjee","year":"2025","journal-title":"Nano TransMed"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"114301","DOI":"10.1016\/j.ejmech.2022.114301","article-title":"Development of inhibitors targeting glycogen synthase kinase-3\u03b2 for human diseases: Strategies to improve selectivity","volume":"236","author":"Wei","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1021\/acschemneuro.3c00096","article-title":"PROTAC-Induced Glycogen Synthase Kinase 3\u03b2 Degradation as a Potential Therapeutic Strategy for Alzheimer\u2019s Disease","volume":"14","author":"Guardigni","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Pradeepkiran, J.A., and Reddy, P.H. (2021). Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer\u2019s disease and tauopathies. Biochim. Et Biophys. Acta (BBA)-Mol. Basis Dis., 1867.","DOI":"10.1016\/j.bbadis.2021.166162"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.4103\/1673-5374.303017","article-title":"Application of PROTAC strategy to TTR-A\u03b2 protein-protein interaction for the development of Alzheimer\u2019s disease drugs","volume":"16","author":"Ciccone","year":"2021","journal-title":"Neural Regen. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/17568919.2025.2463310","article-title":"Advancements in PROTAC-based therapies for neurodegenerative diseases","volume":"17","author":"Kong","year":"2025","journal-title":"Future Med. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1021\/acsmedchemlett.9b00283","article-title":"Treatment of Cancer and Alzheimer\u2019s Disease by PROTAC Degradation of EGFR","volume":"10","author":"Kargbo","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"8177","DOI":"10.1038\/s41467-023-44031-2","article-title":"Harnessing PROTAC technology to combat stress hormone receptor activation","volume":"14","author":"Gazorpak","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e202309706","DOI":"10.1002\/ange.202309706","article-title":"Entdeckung eines potenten PROTAC erm\u00f6glicht die gezielte Ausschaltung der Ger\u00fcstfunktionen von FKBP51","volume":"136","author":"Geiger","year":"2024","journal-title":"Angew. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Wu, J., Li, L., Zhu, Q., Zhang, T., Miao, F., Cui, Z., Dong, G., Tai, Z., and Chen, Z. (2024). JAK1\/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis. Biomed. Pharmacother., 171.","DOI":"10.1016\/j.biopha.2024.116167"},{"key":"ref_91","unstructured":"Colleoni, A., Fassi, E., Miluzio, A., Albani, M., Lecchi, D., Tempra, G., De Amici, M., Grazioso, G., Biffo, S., and Matera, C. (2024, January 13\u201315). Targeted degraders of eIF6: A novel strategy to remodulate liver pathological lipidic metabolism. Proceedings of the Merck Young Chemists\u2019 Symposium (MYCS), Rimini, Italy."},{"key":"ref_92","unstructured":"Colleoni, A., Fassi, E., Miluzio, A., Tempra, G., Albani, M., De Amici, M., Grazioso, G., Biffo, S., and Matera, C. (2025, January 27\u201331). Exploiting the Potential of Computational Approaches in Medicinal Chemistry: CADD of Novel eIF6 Binders for the Development of anti-HCC PROTACs. Proceedings of the WIDEnzymes, Lecco, Italy."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"9184","DOI":"10.1021\/acs.jmedchem.3c00822","article-title":"Discovery of NAFLD-Improving Agents by Promoting the Degradation of Keap1","volume":"66","author":"Qi","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Wang, Y., Zheng, J., Long, Y., Wu, W., and Zhu, Y. (2024). Direct degradation and stabilization of proteins: New horizons in treatment of nonalcoholic steatohepatitis. Biochem. Pharmacol., 220.","DOI":"10.1016\/j.bcp.2023.115989"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1002\/ange.201913904","article-title":"Development of a pde\u03b4-targeting PROTACs that impair lipid metabolism","volume":"132","author":"Winzker","year":"2020","journal-title":"Angew. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Wang, C., Zhang, Y., Xing, D., and Zhang, R. (2021). PROTACs technology for targeting non-oncoproteins: Advances and perspectives. Bioorganic Chem., 114.","DOI":"10.1016\/j.bioorg.2021.105109"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Tashima, T. (2023). Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier. Antibodies, 12.","DOI":"10.3390\/antib12030043"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/17460441.2021.1915979","article-title":"Is PROTAC technology really a game changer for central nervous system drug discovery?","volume":"16","author":"Farrell","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: Great opportunities for academia and industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.tips.2025.01.001","article-title":"IRAK4: Potential therapeutic target for airway disease exacerbations","volume":"46","author":"Jude","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-022-00999-9","article-title":"PROTACs: Great opportunities for academia and industry (an update from 2020 to 2021)","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1039\/D2CS00141A","article-title":"Degrader-antibody conjugates","volume":"51","author":"Dragovich","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1021\/acs.bioconjchem.3c00366","article-title":"Antibody-proteolysis targeting chimera conjugate enables selective degradation of receptor-interacting serine\/threonine-protein kinase 2 in HER2+ cell lines","volume":"34","author":"Chan","year":"2023","journal-title":"Bioconjugate Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.7150\/thno.102531","article-title":"A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"23487","DOI":"10.1002\/ange.202107347","article-title":"Aptamer-protac conjugates (apcs) for tumor-specific targeting in breast cancer","volume":"133","author":"He","year":"2021","journal-title":"Angew. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.1021\/acsnano.2c10379","article-title":"Aptamer-Based Targeted Protein Degradation","volume":"17","author":"Liu","year":"2023","journal-title":"ACS Nano"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/17576180.2025.2459528","article-title":"PROTACs coupled with oligonucleotides to tackle the undruggable","volume":"17","author":"Zhang","year":"2025","journal-title":"Bioanalysis"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.1038\/s41467-021-27210-x","article-title":"Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity","volume":"12","author":"Lv","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Cheng, J., Dong, G., Wang, W., and Sheng, C. (2025). Precise Modulation of Protein Degradation by Smart PROTACs. ChemBioChem, 26.","DOI":"10.1002\/cbic.202400682"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"12273","DOI":"10.1021\/acs.jmedchem.1c00901","article-title":"Folate-guided protein degradation by immunomodulatory imide drug-based molecular glues and proteolysis targeting chimeras","volume":"64","author":"Chen","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"8902","DOI":"10.1021\/jacs.1c03852","article-title":"TF-PROTACs enable targeted degradation of transcription factors","volume":"143","author":"Liu","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Fan, L., Tong, W., Wei, A., and Mu, X. (2024). Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment. Int. J. Biol. Macromol., 275.","DOI":"10.1016\/j.ijbiomac.2024.133680"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Zografou-Barredo, N.A., Hallatt, A.J., Goujon-Ricci, J., and Cano, C. (2023). A beginner\u2019s guide to current synthetic linker strategies towards VHL-recruiting PROTACs. Bioorganic Med. Chem., 88\u201389.","DOI":"10.1016\/j.bmc.2023.117334"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1073\/pnas.1217206110","article-title":"Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs","volume":"110","author":"Hines","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1021\/acsptsci.4c00733","article-title":"Targeting Tau Protein with Proximity Inducing Modulators: A New Frontier to Combat Tauopathies","volume":"8","author":"Uliassi","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1021\/acsptsci.2c00089","article-title":"Novel Design Strategies to Enhance the Efficiency of Proteolysis Targeting Chimeras","volume":"5","author":"Zhao","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1021\/jacs.2c11706","article-title":"Targeted dephosphorylation of tau by phosphorylation targeting chimeras (PhosTACs) as a therapeutic modality","volume":"145","author":"Hu","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"eadj7251","DOI":"10.1126\/sciadv.adj7251","article-title":"EGFR targeting PhosTACs as a dual inhibitory approach reveals differential downstream signaling","volume":"10","author":"Hu","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Negi, A., and Voisin-Chiret, A.S. (2022). Strategies to reduce the on-target platelet toxicity of Bcl-xL inhibitors: PROTACs, SNIPERs and prodrug-based approaches. ChemBioChem, 23.","DOI":"10.1002\/cbic.202100689"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Negi, A., Kesari, K.K., and Voisin-Chiret, A.S. (2022). Light-Activating PROTACs in Cancer: Chemical Design, Challenges, and Applications. Appl. Sci., 12.","DOI":"10.3390\/app12199674"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"18370","DOI":"10.1021\/jacs.9b06422","article-title":"Light-Induced Protein Degradation with Photocaged PROTACs","volume":"141","author":"Xue","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cmdc.202000249","article-title":"Controlling PROTACs with Light","volume":"15","author":"Verma","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1039\/D3CB00199G","article-title":"Click chemistry in the development of PROTACs","volume":"5","author":"Yang","year":"2023","journal-title":"RSC Chem. Biol."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Noblejas-L\u00f3pez, M.d.M., T\u00e9bar-Garc\u00eda, D., L\u00f3pez-Rosa, R., Alcaraz-Sanabria, A., Crist\u00f3bal-Cueto, P., Pinedo-Serrano, A., Rivas-Garc\u00eda, L., and Gal\u00e1n-Moya, E.M. (2023). TACkling cancer by targeting selective protein degradation. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15102442"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"100092","DOI":"10.1016\/j.cellin.2023.100092","article-title":"Antiviral PROTACs: Opportunity borne with challenge","volume":"2","author":"Liang","year":"2023","journal-title":"Cell Insight"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Piret, J., and Boivin, G. (2021). Pandemics Throughout History. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.631736"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/1751-7915.14053","article-title":"The beginning and ending of a respiratory viral pandemic-lessons from the Spanish flu","volume":"15","year":"2022","journal-title":"Microb. Biotechnol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Miranda, M.N.S., Pingarilho, M., Pimentel, V., Torneri, A., Seabra, S.G., Libin, P.J.K., and Abecasis, A.B. (2022). A Tale of Three Recent Pandemics: Influenza, HIV and SARS-CoV-2. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.889643"},{"key":"ref_129","unstructured":"Hatchett, R., and Moreira, M. (2024). We can stop the next pandemic, but only if we act now. Telegraph."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"103395","DOI":"10.1016\/j.drudis.2022.103395","article-title":"PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery","volume":"28","author":"Guedeney","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-pharmtox-022123-104147","article-title":"From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation","volume":"64","author":"Oleinikovas","year":"2024","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1021\/acs.jmedchem.1c00895","article-title":"Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery","volume":"64","author":"Dong","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01146-7","article-title":"Protein degradation technology: A strategic paradigm shift in drug discovery","volume":"14","author":"Li","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC Technology: Opportunities and Challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"112981","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/10\/2123\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:30:50Z","timestamp":1760031050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/10\/2123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,11]]},"references-count":136,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["molecules30102123"],"URL":"https:\/\/doi.org\/10.3390\/molecules30102123","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,11]]}}}